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To explore the role of Interkeulin-31 (IL-31) in dilated cardiomyopathy (DCM), in our study, two SNPs of IL-31, rs4758680
(C/A) and rs7977932 (C/G), were analyzed in 331 DCM patients and 493 controls in a Chinese Han population. The
frequencies of C allele and CC genotype of rs4758680 were significantly increased in DCM patients (P = 0 005, P = 0 001,
resp.). Compared to CC genotype of rs4758680, the A carriers (CA/AA genotypes) were the protect factors in DCM
susceptibility while the frequencies of CA/AA genotypes were decreased in the dominant model for DCM group (P < 0 001,
OR = 0.56, 95%CI = 0.39–0.79). Moreover, IL-31 mRNA expression level of white blood cells was increased in DCM patients
(0.072 (0.044–0.144) versus 0.036 (0.020–0.052), P < 0 001). In survival analysis of 159 DCM patients, Kaplan-Meier curve
revealed the correlation between CC homozygote of rs4758680 and worse prognosis for DCM group (P = 0 005). Compared to
CC genotype, the CA/AA genotypes were the independent factors in both univariate (HR= 0.530, 95%CI = 0.337–0.834,
P = 0 006) and multivariate analyses after age, gender, left ventricular end-diastolic diameter, and left ventricular ejection
fraction adjusted (HR= 0.548, 95%CI = 0.345–0.869, P = 0 011). Thus, we concluded that IL-31 gene polymorphisms were tightly
associated with DCM susceptibility and contributed to worse prognosis in DCM patients.
1. Introduction
Dilated cardiomyopathy (DCM) as a primary myocardial
disease is marked by dilation of the left ventricle as well as
systolic dysfunction that is with progressive functional and
structural changes [1, 2]. It affects −1/2500 adults and more
common in men than in women [3, 4]. DCM is one of the
pivotal causes of sudden cardiac death and congestive
heart failure concurrent with the main indication for heart
transplantation [5, 6]. Over the last years, substantial studies
have focused on the etiology and development of DCM,
whereas the exact cause of DCM was still not understood.
Increasing evidence supports several cytokines implicated
in the inflammatory, and immune responses are partici-
pating in the pathological process of DCM even congestive
heart failure [7, 8]. It has been delineated that the gene
polymorphisms of proinflammatory cytokines such as inter-
leukin- (IL-) 6 and tumor necrosis factor-α (TNF-α) are
associated with the susceptibility and prognosis of DCM
or heart failure [7–9].
Interleukin-31 (IL-31) is a novelly detected proinflam-
matory cytokine belonging to gp130/IL-6 cytokine family
which includes IL-6, IL-11, IL-27, oncostatin M, cardiotro-
phin-1, cardiotrophin-like cytokine, and leukemia inhibitory
factor [10, 11]. It is produced principally by the activated
CD4+ T cells, especially when cells are skewed toward a
Th2 phenotype [10, 12]. Distinguished with gp130 family, it
acts through a heterodimeric receptor consisting of IL-
31RA which is gp130-like receptor and oncostatin receptor
(OSMR) [10]. As previously reported, IL-31 significantly
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stimulated the secretion of proinflammatory cytokines, such
as IL-6 from monocytes and macrophages [13] and human
colonic subepithelial myofibroblasts [14]. IL-6 could induce
a hypertrophic response in myocytes [15], and TNF-α could
trigger the left ventricular dilation [16]. In addition, the
available data exhibited that IL-31 contributed to atopic
dermatitis [17, 18], nonatopic eczema [19], systemic lupus
erythematosus (SLE) [20], asthma [21], inflammatory
bowel disease (IBD) [14], familial primary cutaneous amy-
loidosis [22], Kawasaki disease [23], hepatitis B virus liver
failure [24], and allergic rhinitis [25]. These observations
imply that IL-31 may contribute to the pathogenesis of
DCM via cytokine modulation of immune response.
However, thus far, no study on the correlation between
IL-31 and DCM was reported. Therefore, we conducted the
pilot study to clarify the role of IL-31 in DCM patients in a
Chinese population.
2. Materials and Methods
2.1. Study Subjects. The case group contained 331 subjects
(male/female: 214/117, mean age: 50.16± 14.01 years) diag-
nosed as DCM recruited from the West China Hospital from
June 2002 to October 2015. Since the median of the left
ventricular ejection fraction (LVEF) among DCM patients
was 30%, DCM patients were divided into two groups
(LVEF < 30% versus LVEF ≥ 30%) in SNP-stratified analysis.
The diagnosis of DCM was made in consistent with the
criteria established by the World Health Organization/
International Society and Federation of Cardiology Task
Force on the Classification of Cardiomyopathies in 1995
(before 2006) and the scientific statement on the definitions
and classification of cardiomyopathies proposed by the
American Heart Association in 2006 (after 2006) [2, 26].
Meanwhile, for comparison, we recruited the control
group from a routine health survey, and finally, 493 healthy
unrelated individuals (male/female: 312/181, mean age:
49.15± 8.82 years) were consecutively enrolled. The patients
with hypertension, coronary heart disease, cardiac valve dis-
ease, tachyarrhythmia, acute viral myocarditis, heavy alcohol
intake, skeletal myopathies, systemic diseases of putative
autoimmune origin, diabetes, and obesity or insulin resis-
tance were excluded from the study. Written informed
consents were obtained from all included subjects, sequen-
tially, and 10mL of peripheral venous blood was drawn from
each of the DCM patient and control subjects. The present
study was approved by the hospital ethics committee.
2.2. Extraction of DNA and Genotyping. Genomic DNA was
extracted from 200μl EDTA-anticoagulated peripheral blood
sample with a DNA isolation kit (BioTeke, Peking, China)
as the manufacturer’s direction. DNA was stably stored at
−20°C until assayed. Genotyping of the IL-31 gene poly-
morphism was conducted by polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP).
We designed the PCR primers with software Primer 3
(http://bioinfo.ut.ee/primer3‐0.4.0/primer3/) [27] as shown
in Table 1. The 10μl PCR reaction system was consisted
of 1.0μl DNA and 5μl 2× Power Taq PCR Master Mix
(BioTeke, Peking, China), forward and reverse primer
0.1μl, respectively, and reserved volume was made up to
10μl by sterilized water. The PCR condition was designed
as 95°C for 4min firstly, then 33 cycles at 95°C for 30 s,
60°C for 30 s, and 72°C for 30 s, and finally, 72°C for
10min. Furthermore, the PCR products were digested in
37°C stable incubation by distinguished restriction enzyme
MboII (New England Biolabs, Peking, China) for 30 minutes
of rs4758680 and ScrFI (New England Biolabs, Peking,
China) for 2 hours of rs7977932 as shown in Table 1, sepa-
rately. Ultimately, the results were visually analyzed by 6%
polyacrylamide gels in silver staining. To verify the genotyp-
ing results, DNA sequencing was performed in about 20%
PCR-amplified DNA samples randomly.
2.3. mRNA Isolation, Reverse Transcription, and Quantitative
Real-Time PCR (qPCR). Quantitative real-time PCR of
IL-31 was conducted in 41 DCM patients and 49 controls.
Total RNA was isolated from white blood cells (WBCs)
with TRIzol reagent (Invitrogen, Karlsruhe, Germany) and
then was reverse-transcribed into cDNA, using the Bioneer
kit (R&D Center, Korea) following the manufacturer’s
protocols. Actin was chosen as a reference parameter to
normalize the data. The sense and anti-sense primers
for IL-31 and Actin were 5′-CTCACTCAGGCCCCTCG
AC-3′ and 5′-GTCGTAGTAAACGGACGGGC-3′, 5′-TGA
CGTGGACATCCGCAAAG-3′ and 5′-CTGGAAGGTGGA
CAGCGAGG-3′, respectively.
The qPCR settings in triplicate carried on a MasterCycler
realplex4 (Eppendorf, Wesseling-Berzforf, Germany) using
SYBR Green were as follows: an initial activation step of
10min at 95°C, subsequently by two-step cycling for 25 times:
denaturation of 15 s at 94°C, and annealing and extension
of 20 s at 60°C. Melting curve was added to check the
amplification specificity. 2−△ct method was used to calculate
the mRNA expression levels [28].
Table 1: Information about PCR-RFLP in DCM and control groups.












F:5′-GATCACCCGGACTCAAAACGTG-3’ C/A 263 60 MboII A (263)
R: 5′-TTGTGCAAACCACACCTCTTCG-3’ — — — — C (210 + 53)
rs7977932
F:5′-GGTCAGTGTTGGGTTTGCAATG-3’ C/G 121 60 ScrFI G (74 + 57)
R:5′-TTGGTGATGGCACAGCCTCATA-3’ — — — — C (131)
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2.4. Patients’ Clinical Characteristics and Follow-Up. One
hundred and fifty-nine DCM patients who have reserved
contact information were brought into follow-up plan every
three months until September 13, 2016. Basic clinical mate-
rials of enrolled DCM patients were obtained from the
medical records (age, gender, etc.) and echocardiographic
measurement using a S5-1 broadband phased-array trans-
ducer (1–5MHz). According to the recommendations of
the American Society of Echocardiography, we conducted
a comprehensive 2D and Doppler echocardiography. The
echocardiographic indicators such as the left ventricular
end-diastolic diameter (LVEDD) were calculated with M-
mode echocardiography with the left parasternal window
while the left ventricular ejection fraction (LVEF) was
accessed by apical two- and four-chamber views with the
modified Simpson rule. The follow-up end point was patient’s
death because of heart failure or sudden cardiac events. A
blind manner about patient’s genetic status was applied
during clinical follow-up.
2.5. Statistical Analysis.Quantitative variables were presented
as median and interquartile range (IQR: Q25%–Q75%) and
categorical variables as number of observations. Normality
was tested using Shapiro-Wilk’s test for normality. Differ-
ences between two independent samples for continuous
data were analyzed using the Mann–Whitney U test since
the distributions were different from normal. For categor-
ical variables, statistical analysis was based on Pearson’s
chi-square test.
The allelic and genotype frequencies were obtained by
number counting. The differences of genotypes between the
DCM and control groups including codominant, dominant,
recessive, and overdominant genetic models were analyzed
by using SNPStats online program; meanwhile, odds ratio
and 95% confidence intervals were obtained accordingly [29].
Allelic association andHardy-Weinberg equilibriumwere
assessed with chi-square test. IL-31 WBC mRNA expression
level was compared using the Mann–Whitney test (for two
independent groups) and Kruskal-Wallis H test withmultiple
comparisons post hoc tests according to the results from
Shapiro-Wilk’s test for normality.
Kaplan-Meier curve and Cox proportional hazardmodels
were applied to evaluate the role of IL-31 SNPs on prognosis
in DCM patients. P value less than 0.05 was regarded as
statistically significant.
3. Results
3.1. Baseline Characteristics of DCM Patients and the
Controls. As shown in Table 2, between the DCM patients
and the controls, gender did not exhibit statistically signifi-
cant differences (P = 0 689). Compared to controls, DCM
patients were older (P = 0 022) and had lower systolic blood
pressure (SBP), diastolic blood pressure (DBP), left ven-
tricular ejection fraction (LVEF), higher left ventricular
end-diastolic diameter (LVEDD), and brain natriuretic pep-
tide (BNP) (P < 0 001, resp.) as well as more severe NYHA
functional class (P < 0 001). All DCM patients accepted
medication treatment according to the clinical guidelines
for DCM and heart failure.
3.2. Associations between IL-31 SNPs and Susceptibility for
DCM and DCM Patients’ Characteristics. The gene polymor-
phisms of IL-31 rs4758680 and rs7977932 were identified to
compare the allelic and genotype frequencies of 331 DCM
patients to 493 controls through direct counting. About
20% PCR-amplified DNA samples were randomly evaluated
by DNA sequencing, and the PCR-RFLP results were
manifested as 100% accurate. The distribution of both
rs4758680 and rs7977932 alleles in control groups was
line with the postulation of Hardy-Weinberg equilibrium
(χ2 = 1 876, P = 0 17 for rs4758680; χ2 = 0 004, P = 0 95
for rs7977932).
As shown in Table 3, the strikingly statistical difference
was discovered at rs4758680. The allele frequency of C of
SNP rs4758680 in DCM patients was significantly elevated
compared with that in controls (89.6% versus 84.8%); in
contrast, the allele A frequency was declined (10.4% ver-
sus 15.2%, P = 0 005, OR=0.65, 95%CI=0.48–0.88) in case
group. In codominant model, the frequencies of the CC,
CA, and AA genotypes of rs4758680 were 83.1%, 13.0%,
and 3.9% in cases and were 73.2%, 23.1%, and 3.6% in con-
trols, respectively. The differences among genotype frequen-
cies were statistically significant (P = 0 001). In dominant
model, compared with CC genotype, a notably decreased
DCM risk was related with CA/AA genotypes (P < 0 001,
Table 2: Baseline characteristics of the DCM patients and the controls.
Variables DCM patients (n = 331) Controls (n = 493) P value
Age (years) 52 (43–60) 50 (42–57) 0.022
Gender (male/female) 214/117 312/181 0.689
SBP (mmHg) 116 (109–123) 121 (114–127) <0.001
DBP (mmHg) 73 (68–77) 77 (72–81) <0.001
NYHA II: 62; III: 210; IV: 59 I: 395; II: 98 <0.001
LVEDD (mm) 67 (62–73) 46 (44–49) <0.001
LVEF (%) 30 (25–37) 62 (58–66) <0.001
BNP (pg/ml) 2787 (1600–3836) 95 (83–108) <0.001
Data are exhibited as the median ± interquartile range(IQR: Q25%–Q75%) or number; DCM: dilated cardiomyopathy; SBP: systolic blood pressure;
DBP: diastolic blood pressure; NYHA: New York Heart Association; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction;



















































































































































































































































































































































































































































































































































































































































































OR=0.56, 95%CI= 0.39–0.79). Subjects with heterozygous
genotype (CAgenotype)of rs4758680haddistinctly decreased
risks for DCM compared with the CC/AA genotypes in
overdominant model (P < 0 001, OR=0.50, 95%CI=0.34–
0.73). As shown in Table 3, there was no significant differ-
ence described between DCM patients and controls in
rs7977932 gene polymorphism analysis. To provide insights
into the effects of IL-31 SNPs on DCM, we exhibited the
stratified analyses among 331 DCM patients. After adjusted
by age and gender, the association between rs4758680 of
IL-31 and LVEF was shown in Table 4 which revealed that
the heterozygote CA was the protect factor for DCM patients
whose LVEF was <30% compared with those LVEF was
≥30% (P = 0 042). There were no statistically significant
differences between the two SNPs of IL-31 (rs4758680 and
rs7977932) and LVEDD.
3.3. IL-31 WBC mRNA Expression Level. The median and
IQR of 2−△ct result among 41 DCM patients were 0.072
(0.044–0.144), while it was 0.036 (0.020–0.052) among 49
controls, and the difference for IL-31 WBC mRNA expres-
sion between DCM group (n = 41) and control group
(n = 49) was statistically significant (P < 0 001) as shown in
Figure 1(a). To probe into the functional influence of the
IL-31 (rs4758680) genotype polymorphism (CC, CA, and
AA genotypes) on the IL-31 WBC mRNA expression, the
quantitative IL-31 mRNA results among different genotypes
were analyzed. The IL-31 mRNA results for CA/AA geno-
types in DCM (n = 21) and controls (n = 22) were 0.087
(0.044–0.223) and 0.038 (0.021–0.050), and those for CC
genotype in DCM (n = 20) and controls (n = 27) were 0.065
(0.044–0.124) and 0.033 (0.018–0.065). As Figure 1(b)
delineated, the P value was less than 0.001 for Kruskal-
Wallis H test and the results of multiple comparisons post
hoc tests revealed that there were statistically significant
differences for IL-31 mRNA level between CA/AA genotypes
in DCM and CA/AA genotypes in controls, CC genotype in
DCM and CA/AA genotypes in controls, CA/AA genotypes
in DCM and CC genotype in controls, and CC genotype in
DCM and CC genotype in controls (P < 0 001, resp.). There
were no statistically significant differences between CA/AA
genotypes and CC genotype in DCM, as well as in controls
(P = 0 191, 0.389, resp.).
3.4. Survival Analysis of IL-31 Genotypes in DCM Patients.
The prognosis of DCM associated with two SNPs of IL-31
gene was carried out by survival analysis. 159 DCM patients
(mean age, 51.03± 13.43 years; male/female, 107/52) were
tracked for a mean period of three months. 20 DCM patients
were lost during the follow-up. During the follow-up, all
included patients accepted consecutive medication treatment
and none underwent heart transplantation.
Whenendingup the follow-up, 104 (65.4%)DCMpatients
died ascribable to cardiac events. The baseline characteristic
differences between 104 dead DCM patients and 35 survival
DCM patients were described in Supplementary Table
available online at https://doi.org/10.1155/2017/4191365,
and there were no statistically significant differences between
the two analyzed groups for gender, SBP, DBP, and LVEDD
(P = 0 251, 0.789, 0.431, and 0.817, resp.). By contrast, dead
DCM patients were younger (P = 0 036) and had worse
NYHA functional class (P < 0 001), lower LVEF (P = 0 025),
and higher BNP (P = 0 020).
Kaplan-Meier curves indicated that CC homozygote
and CC/AA genotypes of IL-31 rs4758680 were implicated
in worse prognosis for DCM patients, respectively (Log-
rank: P = 0 005, Figure 2; Log-rank: P = 0 009, Figure 3).
Cox univariate survival analysis revealed A carriers (CA/
AA genotypes) were correlated with better prognosis com-
pared to CC genotype in genetic dominant model for
DCM patients (HR=0.530, 95%CI= 0.337–0.834, P = 0 006,
Table 5). Similarly in overdominant model of rs4758680,
compared to CC and AA homozygotes, heterozygote
CA accounted for better prognosis for DCM patients
(HR=0.516, 95%CI=0.310–0.861, P = 0 011, Table 5).
After adjusting for age, gender, LVEDD, and LVEF, the
associations between A carriers (CA/AA genotypes), CA
heterozygote of rs4758680, and prognosis of DCM were
still statistical significant for both dominant and over-
dominant models in multivariate Cox proportional hazard
model analysis (HR=0.548, 95%CI= 0.345–0.869, P = 0 011
and HR=0.503, 95%CI= 0.297–0.852, P = 0 011, Table 5,
resp.). There were no statistical differences between IL-31
rs4758680 recessive model as well as rs7977932 gene poly-
morphism and overall survival time in univariate and multi-
variate Cox proportional hazard models as shown in Table 5.
4. Discussion
As previously reported, although the etiology and pathogen-
esis of DCM were complicated, chronic inflammation might
contribute to cardiac remodeling and the development of
DCM [30], and abnormal immune responses were proposed
to be prominent factors in the DCM process especially after
myocarditis [31]. Inflammatory cytokines like IL-6 in con-
junction with TNF-α participated in myocyte apoptosis and
myofibrosis which were involved in DCM [15, 32].
Beyond that, the established studies validated that IL-31
as a novel inflammatory cytokine was a potent inducer of
proinflammatory mediators such as IL-6 in various cell types,
including epithelial cells, colonic subepithelial myofibro-
blasts, PBMCs, macrophages, and eosinophils [33]. Matrix
metalloproteinases (MMPs) also can be induced by IL-31 in
colonic subepithelial myofibroblasts of IBD [14] and their
higher serum level was involved in continuous extracellu-
lar matrix remodeling and increased collagen turnover of
DCM with mildly dilated left ventricle [34, 35]. Shen et al.
revealed that inhibition of MMPs, especially MMP-2, could
reduce apoptosis from TNF-α in cultured cardiac myocytes
[36]. In the past few years, IL-31 receptor was principally
found in the skin, brain, lung, skeletal muscle, ovary, testis,
prostate, spleen, thymus, bone marrow, and more [10]. In
coincident with IL-31 receptor distribution, IL-31 was already
identified to be associated with immune-dysfunction diseases
such as atopic dermatitis, SLE, and asthma.
The established studies suggested that soluble IL-31RA
might expand the range of responsive cells and tissues















































































































































































































































































































































































































































































































































































































































































myocarditis had overlapping loci with diabetes and SLE,
suggesting that these autoimmune diseases shared genetic
traits [1]. Similarly, Doria et al. identified that DCM was
one of the most serious complications involved in SLE
[38] and D. Y. Chen et al. have verified that the level of
Th17-related cytokines (containing IL-6, TNF-α) was ele-
vated in SLE-related DCM [39]. These inferences imply a
possible role of IL-31 in immune response and in DCM
pathogenesis process.
The present study was the first one to investigate the
correlation between IL-31 and DCM in a Han Chinese pop-
ulation. The human IL-31 gene is located on chromosome
12q24.31 and encodes a protein with 164 amino acids. Both
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Figure 3: Kaplan-Meier survival curves for the overdominant
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Figure 1: Comparsion of WBC IL-31 mRNA expression level between the DCM patients and the control group (a); comparsions of
WBC IL-31 mRNA expression levels among rs4758680 different genotypes (b). The results were presented on box plots (median,
IQR, range), ∗P < 0 001.
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12 intron region of Homo sapiens which have been
implicated in SLE and AD [19, 20, 40].
Our results showed that genotype frequencies in
the codominant, dominant, and overdominant models of
rs4758680 were associated with DCM susceptibility. The C
allele frequency of rs4758680 (C/A) in DCM was elevated,
whereas the A allele was declined. We manifested that the
C allele was the main predisposing factor and A carriers
(CA/AA genotypes) were the protect factors for DCM
especially in genetic dominant model. The CC genotype
frequency of rs4758680 of IL-31 was also relevance with
DCM worse prognosis in Kaplan-Meier curve and Cox
proportional hazard models. Moreover, in accordance with
SNP results of rs4758680, the IL-31 WBC mRNA expression
level was overtly elevated in DCM group, and the WBC
mRNA expression levels of CC and CA/AA genotypes in
DCM patients were higher than those in control group. As
previously reported, IL-31 acted through the receptor com-
plex of IL-31RA which is gp130-like receptor and OSMR-β.
gp130 has been shown to mediate the cardiotrophin-1
(CT-1) in the heart that resulted in LV hypertrophy [41].
OSMR-β has been proved as increasing expression trend in
DCM patients [42] and signaling in myocardium that result
in loss of sarcomere elements and cardiac fibroblast in mouse
cardiac fibroblasts [43]. Kunsleben et al. delineated that the
calcium influx was induced by IL-31 in eosinophils mainly
through OSMR mediating, which prompt IL-31 may affect
the myocardial contraction [44]. Hence, we concluded that
rs4758680 of IL-31 SNPs played a pathogenic role in DCM
patients by facilitating IL-31 protein production. In our
study, the number of WBC mRNA samples was not large
enough, especially the number of AA genotype was only
three cases and two cases in DCM and controls, respec-
tively. The precise and intricate mechanisms for protein
expression were still unclear, and much more studies will
be indispensable. By contrast, the genotype frequency of
rs7977932 was absence in the DCM susceptibility. As previ-
ously reported, rs7977932 (C/G) genotype polymorphism
of IL-31 was implicated in SLE and AD [20, 40]. The differ-
ence of inclusive quantity or disease essence between our
study in DCM and the previous one in SLE may account
for the inconsistency of rs7977932 effect.
5. Conclusions
In conclusion, IL-31 as scratch factor was a research hot spot
before we firstly revealed that rs4758680 (C/A) of IL-31 was
associated with the susceptibility of DCM in the Chinese
Han people although larger sample sizes of IL-31 SNP would
be necessary to confirm our findings; moreover, CC genotype
was implicated in the worse prognosis in DCM group. Even
so, plasma IL-31 protein level and the underlying mecha-
nisms were lack in our study; besides, more SNPs of IL-31
with DCM susceptibility and prognosis in a variety of ethnic
populations need to be investigated in future studies.
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Table 5: Associations between IL-31 SNPs and patients’ overall survival.
Characteristics Genotype
Overall survival
Multivariate survival analysisa Univariate survival analysis




CC 1 — — 1 — —
CA/AA 0.548 0.345–0.869 0.011 0.530 0.337–0.834 0.006
Recessive
CC/CA 1 — — 1 — —
AA 0.868 0.399–1.888 0.722 0.778 0.361–1.678 0.522
Overdominant
CC/AA 1 — — 1 — —
CA 0.503 0.297–0.852 0.011 0.516 0.310–0.861 0.011
rs7977932
Dominant
CC 1 — — 1 — —
CG/GG 1.161 0.666–2.024 0.599 1.275 0.736–2.211 0.386
Recessive
CC/CG 1 — — 1 — —
GG 3.739 0.862–16.218 0.078 3.482 0.841–14.414 0.085
Overdominant
CC/GG 1 — — 1 — —
CG 1.096 0.619–1.943 0.753 1.211 0.687–2.133 0.508
aMultivariate survival analysis adjusted for age, gender, LVEDD, and LVEF.
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